Researchers from the Icahn School of Medicine at Mount Sinai have discovered a promising new way to improve CAR-T cell therapy for solid tumors such as lung cancer and melanoma. The study, published in Nature Cancer (https://www.nature.com/articles/s43018-026-01167-6), found that focused irradiation, a targeted therapy that delivers high-energy beams to stun rapidly growing cells such as cancer, can help CAR-T cells survive longer and work more effectively inside tumors. 

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers.

A recent review provides an overview of the purinergic receptor P2Y2 and its involvement in cancer-related processes. The article discusses how extracellular nucleotide signaling may influence tumor cell behavior and the tumor microenvironment, and evaluates the potential of P2Y2 as a biomarker and therapeutic target.

Martin G. Pomper, MD, PhD, known for his pioneering work in molecular imaging and the development of prostate-specific membrane antigen (PSMA) targeted agents, was awarded the Benedict Cassen Prize during the Society of Nuclear Medicine and Molecular Imaging 2026 Annual Meeting. The honor is awarded every two years by the Education and Research Foundation (ERF) for Nuclear Medicine and Molecular Imaging in recognition of outstanding achievement and work leading to a major advance in nuclear medicine science.